U.S. Hormone Replacement Therapy Market - By Product (Estrogen, Progesterone, Thyroid, Growth Hormone, Testosterone), Route of Administration (Oral, Parenteral), Disease (Menopause, Growth Hormone Deficiency), Distribution Channel, Forecast 2023-2032

U.S. Hormone Replacement Therapy Market Size

The U.S. Hormone Replacement Therapy Market size in 2022 was evaluated to be USD 6.9 billion and is anticipated to be valued at USD 13.4 billion by 2032. The aging U.S. population, with a significant number of women reaching menopausal stages, is a primary driver of the HRT market. As people age, there is an increased prevalence of hormonal imbalances and associated symptoms, resulting in a heightened demand for hormone replacement therapies.
 

Furthermore, rising cases of thyroid disorders and other endocrine disorders is aiding the market progress. For instance, as per a study published by NIH, in 2022, prevalence of hypothyroidism (HT) was approximately 4.6% in the U.S. population. Additionally, with a surge in the number of specialized clinics and healthcare providers offering HRT coupled with a paradigm shift towards personalized and preventative healthcare in the market is poised to witness high growth.

COVID-19 Impact

The COVID-19 pandemic had a disruptive impact on the market, particularly by affecting the global supply chain and consequently influencing the distribution of hormone replacement therapy worldwide. Further, the lockdown measures posed difficulties for both patients and healthcare practitioners, thereby impeding the market. According to a study published in April 2022, the COVID-19 crisis had a negative impact on growth hormone treatment compliance, with a considerable impact on other daily life factors such as physical activity, sleep time, leisure screen time, and dietary habits.
 

U.S. Hormone Replacement Therapy Market Trends

The rising prevalence of hormonal disorders serves as a compelling driver for the increased adoption of hormone replacement therapy (HRT). As societies age and lifestyles evolve, there has been a noticeable uptick in the incidence of hormonal imbalances, particularly among the elderly population.
 

• Conditions such as menopause in women and andropause in men, coupled with disorders like hypothyroidism and adrenal insufficiency, contribute to a growing demand for effective hormonal management.
   
• For instance, according to National Institute of Health (NIH), nearly one in 4,000 to 6,000 children and about 50,000 adults suffer from growth hormone deficiency in the U.S. This demographic shift, alongside heightened awareness and diagnostics, propels the need for therapeutic interventions like HRT to restore hormonal equilibrium and enhance the quality of life for those affected.
   

Technological advancements in drug delivery methods have played a pivotal role in driving the hormone replacement therapy (HRT) industry, leading to improved patient adherence, convenience, and treatment outcomes.
 

U.S. Hormone Replacement Therapy Market Analysis

Based on product, the market is segmented into estrogen & progesterone replacement therapy, thyroid replacement therapy, growth hormone replacement therapy, parathyroid hormone replacement therapy, and testosterone replacement therapy. The estrogen & progesterone replacement therapy segment accounted for highest market share of 55.3% in 2022 and is expected to reach USD 7.5 billion by 2032.
 

• Estrogen and progesterone replacement therapy has a well-established track record of effectiveness in managing menopausal symptoms and can be used for postmenopausal osteoporosis treatment. It is considered one of the most effective treatments for addressing these health concerns, which enhances its popularity and market share.
   
• The efficacy and safety of estrogen and progesterone replacement therapy are supported by a substantial body of clinical research and scientific evidence.
   

Based on route of administration, the U.S. hormone replacement therapy market is classified into oral, parenteral, and other routes of administration. In 2022, the oral segment secured the largest market share at 43.5% and is anticipated to exhibit substantial growth from 2023 to 2032.
 

• This growth is attributed to factors like its non-invasive nature, precise and consistent drug dosing, affordability, and the strong preference of patients.
   
• Oral HRT ensures a consistent dosing regimen, simplifying treatment management for both patients and healthcare providers. The steady and predictable delivery of hormones facilitates monitoring and adjustment of treatment plans.
   

By disease type, the U.S. hormone replacement therapy market is segmented into menopause, hypothyroidism, growth hormone deficiency, hypoparathyroidism, male hypogonadism, and other disease type. In 2022, the menopause segment accounted for highest market share of 50.5% and is anticipated to witness growth at 7 % during the analysis period.
 

• Menopause is characterized by a range of symptoms, including hot flashes, night sweats, mood swings, sleep disturbances, vaginal dryness, and more. These symptoms can be disruptive and significantly impact a woman's quality of life. HRT provides an effective means of alleviating these symptoms, leading to improved comfort and well-being.
   
• Thus, the large share of the menopause segment can be attributed to the higher usage of HRT for the management of its symptoms, the increasing prevalence of menopause, and the growing availability of various formulation for management of its symptoms.
   

Based on distribution channel, the U.S. hormone replacement therapy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held highest business share of 57.2%.
 

• Hospitals are primary healthcare institutions where patients with various medical conditions, including those requiring HRT, receive comprehensive care.
   
• Further, hospital pharmacies are well equipped to provide the highest quality of care and contribute significantly to the utilization of HRT.
   

U.S. Hormone Replacement Therapy Market Share

The key industry players operating in this market have established themselves through top-notch quality products, advanced technology, and a strong market presence. Novo Nordisk A/S, Pfizer, Inc., and Eli Lilly & Company are prominent leaders in this market. These significant players offer a wide range of solutions for hormonal imbalances and disorders. They are consistently involved in creating new opportunities in the healthcare sector.
 

Market players operating in the U.S. hormone replacement therapy industry is as mentioned below:

• Eli Lilly and Company
• Bayer AG
• Pfizer Inc.
• Viatris, Inc.
• Noven Pharmaceuticals, Inc.
• Merck KGaA
• Novo Nordisk A/S
• F. Hoffmann-La Roche Ltd.
• ASCEND Therapeutics US, LLC.
• Abbott Laboratories
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
   

U.S. Hormone Replacement Therapy Industry News:

• In February 2022, Eli Lily and Company entered a collaboration with Very Inc, an oncology biopharmaceutical company. This is to evaluate enobosarm in combination with verzenio in Phase 3 ENABLAR-2 Trial. This strategy helped to characterize and evaluate the enbosarm efficacy as a hormone replacement therapy and consequently increasing the demand and supply of verzenio, thus increasing the product portfolio of the company. 
   
• In October 2018, Novo Nordisk announced the expansion of its biopharm business with an agreement to acquire the U.S. and Canadian rights to Macrilen, an enhancer of growth hormone secretion and the first and only FDA-approved oral product indicated for the diagnosis of Adult Growth Hormone Deficiency. This strategy prioritized the hormonal deficiency tests and adopting HRT, thereby proliferated the product sales of the company. 

The U.S. hormone replacement therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product, 2018 – 2032 (USD Million)

• Estrogen & progesterone replacement therapy
• Thyroid replacement therapy
• Growth hormone replacement therapy
• Parathyroid hormone replacement therapy
• Testosterone replacement therapy

By Route of Administration, 2018 – 2032 (USD Million)

• Oral
• Parenteral
• Other routes of administration

By Disease Type, 2018 – 2032 (USD Million)

• Menopause
• Growth hormone deficiency
• Male hypogonadism
• Hypothyroidism
• Hypoparathyroidism
• Other disease types

By Distribution Channel, 2018 – 2032 (USD Million)

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies